Crescendo raises GBP4.5m for development of antibody technology platforms
Crescendo Biologics has raised GBP4.5m in a seed-funding led by Sofinnova Partners, to advance the development of its fragment antibody technology platforms.
Today, Pepscan reports that it has achieved a major scientific breakthrough through the use of its CLIPS-based synthetic peptide immunogen technology.